Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Frederick Altice, Obaro Evuarherhe, Sophie Shina, Gemma Carter & Anne Christine Beaubrun. (2019) Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Preference and Adherence 13, pages 475-490.
Read now
Read now
Roberta Prinapori & Antonio Di Biagio. (2015) Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS. Patient Preference and Adherence 9, pages 1213-1218.
Read now
Read now
M Gracia Mateo, M del Mar Gutierrez, Francesc Vidal & Pere Domingo. (2013)
Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS. Expert Opinion on Pharmacotherapy 14:8, pages 1055-1064.
Read now
Read now
Nitipong Permpalung, Opass Putcharoen, Anchalee Avihingsanon & Kiat Ruxrungtham. (2012) Treatment of HIV infection with once-daily regimens. Expert Opinion on Pharmacotherapy 13:16, pages 2301-2317.
Read now
Read now
Jean B Nachega, Bernd Rosenkranz & Paul A Pham. (2011) Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?. Patient Preference and Adherence 5, pages 645-651.
Read now
Read now
Bach
Xuan Tran, Arto Ohinmaa, Long
Thanh Nguyen, Thu
Anh Nguyen & Thao
Huong Nguyen. (2011) Determinants of health-related quality of life in adults living with HIV in Vietnam. AIDS Care 23:10, pages 1236-1245.
Read now
Read now
Articles from other publishers (14)
Sonoe HigashinoTakeo YasuKenji MomoSeiichiro Kuroda. (2022) Effects of raltegravir formulation change on medication adherence and medication errors. Drug Discoveries & Therapeutics 16:4, pages 198-199.
Crossref
Crossref
Pedro Cahn, Paul E. Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan, Mohammed Rassool, Mark Bloch, Xia Xu, Yan Zhou, Brenda Homony, Deborah Hepler, Hedy Teppler, George J. Hanna, Bach-Yen Nguyen & Wayne Greaves. (2018) Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 78:5, pages 589-598.
Crossref
Crossref
Pedro Cahn, Richard Kaplan, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Anchalee Avihingsanon, Winai Ratanasuwan, Evelyn Rojas, Mohammed Rassool, Mark Bloch, Linos Vandekerckhove, Peter Ruane, Yazdan Yazdanpanah, Christine Katlama, Xia Xu, Anthony Rodgers, Lilly East, Larissa Wenning, Sandy Rawlins, Brenda Homony, Peter Sklar, Bach-Yen Nguyen, Randi Leavitt, Hedy Teppler, PE Cahn, I Cassetti, M Losso, MT Bloch, N Roth, J McMahon, RJ Moore, D Smith, N Clumeck, L Vanderkerckhove, B Vandercam, M Moutschen, J Baril, B Conway, F Smaill, GHR Smith, A Rachlis, SL Walmsley, C Perez, M Wolff, MF Lasso, CE Chahin, JD Velez, O Sussmann, J Reynes, C Katlama, Y Yazdanpanah, S Ferret, J Durant, C Duvivier, I Poizot-Martin, F Ajana, JK Rockstroh, G Faetkanheuer, S Esser, H Jaeger, O Degen, M Bickel, J Bogner, K Arasteh, H Hartl, A Stoehr, EM Rojas, E Arathoon, LD Gonzalez, CR Mejia, E Shahar, D Turner, I Levy, Z Sthoeger, H Elinav, A Gori, A D'Arminio Monforte, G Di Perri, A Lazzarin, G Rizzardini, A Antinori, BM Celesia, F Maggiolo, TS Chow, CKC Lee, R Iskandar Shah Raja Azwa, M Mustafa, M Oyanguren, RA Castillo, L Hercilla, C Echiverri, F Maltez, JG Saraiva da Cunha, I Neves, E Teofilo, R Serrao, F Nagimova, I Khaertynova, E Orlova-Morozova, E Voronin, V Sotnikov, AA Yakovlev, NG Zakharova, OA Tsybakova, ME Botes, L Mohapi, R Kaplan, MS Rassool, JR Arribas, JM Gatell, E Negredo, E Ortega, J Troya, J Berenguer, K Aguirrebengoa, A Antela, A Calmy, M Cavassini, A Rauch, M Stoeckle, WH Sheng, HH Lin, HC Tsai, D Changpradub, A Avihingsanon, S Kiertiburanakul, W Ratanasuwan, MR Nelson, A Clarke, A Ustianowski, A Winston, MA Johnson, DM Asmuth, J Cade, JE Gallant, PJ Ruane, PN Kumar, AE Luque, L Panther, KT Tashima, D Ward, DS Berger, CA Dietz, C Fichtenbaum, S Gupta, KM Mullane, RM Novak, DE Sweet, GE Crofoot, DP Hagins, ST Lewis, CK McDonald, E DeJesus, L Sloan, DJ Prelutsky, JC Rondon, S Henn, AJ Scarsella, JO Morales, Ramirez, L Santiago, CD Zorrilla, MS Saag & CB Hsiao. (2017) Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. The Lancet HIV 4:11, pages e486-e494.
Crossref
Crossref
Leonard Emuren, Seth Welles, Alison A. Evans, Marcia Polansky, Jason F. Okulicz, Grace Macalino & Brian K. Agan. (2017) Health-related quality of life among military HIV patients on antiretroviral therapy. PLOS ONE 12:6, pages e0178953.
Crossref
Crossref
Xianhong Li, Ling Li, Honghong Wang, Kristopher P Fennie, Jia Chen & Ann Bartley Williams. (2015) Mediation analysis of health-related quality of life among people living with HIV infection in China. Nursing & Health Sciences 17:2, pages 250-256.
Crossref
Crossref
Sarah J. Tennant, E. Kelly Hester, Celeste R. Caulder, Z. Kevin Lu & P. Brandon Bookstaver. (2014) Adherence among Rural HIV-Infected Patients in the Deep South. Journal of the International Association of Providers of AIDS Care (JIAPAC) 14:1, pages 64-71.
Crossref
Crossref
Andrew Tomita, Nigel Garrett, Lise Werner, Jonathan K. Burns, Nelisiwe Ngcobo, Nomthandazo Zuma, Koleka Mlisana, Francois van Loggerenberg & Salim S. Abdool Karim. (2014) Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the CAPRISA 002 Acute Infection Study. AIDS and Behavior 18:9, pages 1801-1807.
Crossref
Crossref
Kit N Simpson, Kristin A Hanson, Gale Harding, Seema Haider, Margaret Tawadrous, Alexandra Khachatryan, Chris L Pashos & Albert W Wu. (2013) Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health and Quality of Life Outcomes 11:1.
Crossref
Crossref
AM Mills, A Antinori, B Clotet, J Fourie, G Herrera, C Hicks, JV Madruga, S Vanveggel, M Stevens & K Boven. (2013)
Neurological and psychiatric tolerability of rilpivirine (TMC278)
vs.
efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks
. HIV Medicine 14:7, pages 391-400.
Crossref
Crossref
Harleen Gakhar, Amanda Kamali & Mark Holodniy. (2013) Health-related Quality of Life Assessment after Antiretroviral Therapy: A Review of the Literature. Drugs 73:7, pages 651-672.
Crossref
Crossref
Bach Xuan Tran. (2012) Quality of Life Outcomes of Antiretroviral Treatment for HIV/AIDS Patients in Vietnam. PLoS ONE 7:7, pages e41062.
Crossref
Crossref
Bach Tran, Arto Ohinmaa & Long Nguyen. (2012) Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients. Health and Quality of Life Outcomes 10:1, pages 132.
Crossref
Crossref
Janet Raboud, Maggie Li, Sharon Walmsley, Curtis Cooper, Sandra Blitz, Ahmed M. Bayoumi, Sean Rourke, Sergio Rueda, Anita Rachlis, Nicole Mittmann, Marek Smieja, Evan Collins & Mona R. Loutfy. (2010) Once Daily Dosing Improves Adherence to Antiretroviral Therapy. AIDS and Behavior 15:7, pages 1397-1409.
Crossref
Crossref
David R Bangsberg, Kathleen Ragland, Alex Monk & Steven G Deeks. (2010) A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 24:18, pages 2835-2840.
Crossref
Crossref